Chronic Lymphocytic Leukemia Clinical Research Trials

Birmingham : University of Alabama at Birmingham

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Birmingham : Uab Comprehensive Cancer Center

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Huntsville : Clearview Cancer Institute

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Huntsville : Clearview Cancer Institute

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Huntsville : Clearview Cancer Institute

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Huntsville : Clearview Cancer Institute

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Huntsville : Clearview Cancer Institute

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Huntsville : TG Therapeutics Investigational Trial Site

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Huntsville : Clearview Cancer Institute

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Huntsville : TG Therapeutics Investigational Trial Site

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Muscle Shoals : Northwest Alabama Cancer Center, PC

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Tucson : Arizona Oncology Associates

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Tucson : Arizona Oncology Associates

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Tucson : University of Arizona (SPORE)

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Duarte : City of Hope

Acquisition of Peripheral Blood and/or Bone Marrow Aspirate from Patients with Chronic Lymphocytic Leukemia for Method Development of Aptamers Based Delivery Method of RNAi

La Jolla : Moores UCSD Cancer Center

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Santa Maria : Central Coast Medical Oncology Corp.

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Stanford : Stanford University School of Medicine

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Sunnyvale : Pharmacyclics

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Burbank : East Valley Hematology and Oncology Medical Group

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Concord : Bay Area Cancer Research Group

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Duarte : City of Hope National Medical Center Updated

A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

Duarte : City of Hope National Medical Center Updated

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Fountain Valley : Lalita Pandit, MD, Inc.

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Fountain Valley : Pacific Coast Hematology/Oncology Medical Group, Inc.

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Fountain Valley : Robert A. Moss, M.D. FACP, Inc.

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

La Jolla : University of California, San Diego - Moores Cancer Center

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

La Jolla : University of California, San Diego/Moores Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

La Jolla : University of California, San Diego- Moores Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

La Jolla : Scripps Cancer Center

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

La Jolla : Moores UCSD Cancer Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

La Jolla : Moores Ucsd Cancer Center

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

La Jolla : University of California, San Diego

Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

La Jolla : University of California San Diego

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

La Jolla : Moores UCSD Cancer Center

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

La Jolla : UCSD Medical Center

Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Los Angeles : UCLA

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Los Angeles : Metropolitan Hematology Oncology Medical Group

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Los Angeles : Usc - Norris Comprehensive Cancer Center And Hospital

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Los Angeles : Ucla-Division Of Hematology/Oncology

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Los Angeles : UCLA

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Mission Hills : Providence Holy Cross Medical Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Oceanside : North County Oncology

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Oxnard : Ventura County Hematology Oncology Specialists

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Oxnard : Ventura County Hematology Oncology Specialists

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Oxnard : PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Oxnard : Ventura County Hematology Oncology Specialists

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Palo Alto : Stanford Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Palo Alto : Stanford Cancer Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Palo Alto : Stanford Cancer Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Rancho Mirage : Cancer and Blood Institute Medical Group

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Sacramento : University of California Comprehensive Cancer Center

Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma

San Diego : Moores UCSD Cancer Center

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Santa Monica : UCLA Medical Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Santa Monica : UCLA

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Stanford : Stanford Cancer Center

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Stanford : Stanford Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Stanford : Stanford Cancer Center - Stanford University

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Stockton : St. Teresa Comprehensive Cancer Center

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Vista : Medical Group of North County

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Aurora : Investigational Site Number 840004

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

Colorado Springs : The Oncology Clinic, PC

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Denver : Rocky Mountain Blood and Marrow Transplant Program

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Denver : Rocky Mountain Cancer Center

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Denver : Rocky Mountain Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Denver : Rocky Mountain Blood and Marrow Transplant Program

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Denver : Rocky Mountain Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Denver : Rocky Mountain Cancer Centers - Denver

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Denver : Mile High Oncology

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Norwalk : Whittingham Cancer Center at Norwalk Hospital

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

New Haven : Yale Cancer Center

Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

Washington : Georgetown University Medical Center Lombardi Cancer Center

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Washington : Georgetown University Medical Center Lombardi Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Atlantis : Medical Specialists of the Palm Beaches

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Boca Raton :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Boynton Beach : Collaborative Research Group

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Boynton Beach : Collaborative Research Group LLC

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Boynton Beach : University Cancer Institute

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Boynton Beach : Thomas Niederman, MD

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Boynton Beach : Palm Beach Institute of Hematology and Oncology

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Fort Myers : Florida Cancer Specialists

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Fort Myers : Florida Cancer Specialists

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Gainsville : University of Florida

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Gainsville : University of Florida

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Gainsville : University of Florida

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Jacksonville : Integrated Community Oncology Network

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Jacksonville : Mayo Clinic

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Kissimmee : Osceola Cancer Center

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

New Port Richey : Pasco Hernando Oncology Associates (Kumar)

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

New Port Richey : Pasco Hernando Oncology Associates, PA

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

New Port Richey : Pasco Pinellas Cancer Center

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Ocala : Ocala Oncology Center

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

St. Petersburg : Florida Cancer Specialists

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

St. Petersburg : Florida Cancer Specialists

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Albany : Phoebe Putney Memorial Hospital

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Atlanta : Peachtree Hematology Oncology Consultants Updated

A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

Atlanta : Peachtree Hematology Oncology Consultants Updated

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Atlanta : Peachtree Hematology-Oncology Consultants

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Atlanta : Georgia Cancer Specialists

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Augusta : Augusta Oncology Associates, PC

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Augusta : For additional information regarding sites for this trial call (919) 465-4648

Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab in Previously Untreated Chronic Lymphocytic Leukemia

Augusta : Investigational Site Number 840006

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

Dublin : US Oncology - Dublin Hematology & Oncology

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Griffin : Spalding Oncology Services

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Marietta :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Honolulu : Straub Clinic and Hospital

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Boise : St Luke's Mountain States Tumor Institute

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Arlington Heights : US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Arlington

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Chicago : Northwestern University

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Chicago : University of Chicago - Oncology Dept Updated

A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

Chicago : Northwestern University

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Chicago :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chicago : University of Chicago - Oncology Dept Updated

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Chicago : John H. Stroger, Jr., Hospital of Cook County

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Chicago : Rush University Medical Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Chicago : Northwestern University

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Gurnee : Oncology Hematology Assoc. of Northern Illinois

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Harvey : Ingalls Cancer Research Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Lombard : Elmhurst Memorial Hospital

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Niles : Oncology Specialists, S.C.

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Niles : US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Niles

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Peoria : Illinois Cancer Care

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Skokie : Orchard Research

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Urbana : Carle Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Winfield : US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Winfield

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Beech Grove : St. Francis Cancer Research

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Goshen :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Goshen : Center for Cancer Care @ Goshen Health Systems

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Indianapolis :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Indianapolis : Indiana University Simon Cancer Center IU Simon Cancer Center Clinical Research Office, RT 380

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Indianapolis : Indiana University Cancer Center Clinical Research Office

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Indianapolis : Indiana Oncology Hematology Consultants

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Indianapolis : Indiana University Simon Cancer Center

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Lafayette : Arnett Cancer Care

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Lafayette : Horizon Oncology Center

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Mishawaka : Cancer Care Partners, LLC

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

New Albany : Cancer Care Center, Inc.

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

New Albany : Cancer Care Center

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Ames : McFarland Clinic

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Bettendorf : Hematology Oncology Associates of the Quad Cities

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Cedar Rapids : Iowa Blood and Cancer Care of PCI

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Iowa City :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Waterloo : Covenant Clinic

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Wichita : Cancer Center of Kansas, PA

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Hazard : Kentucky Cancer Clinic

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Louisville :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Paducah :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Baton Rouge : Mary Bird Perkins Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Marrero :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Baltimore :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Baltimore : Chesapeake Oncology Hematology Associates

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Baltimore : Auerbach Hematology Oncology Associates, Inc.

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Baltimore : Greater Baltimore Medical Center

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Baltimore : B. Douglas Smith, M.D.

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Bethesda : Center for Cancer & Blood Disorders, PC

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Bethesda : TG Therapeutics Investigational Trial Site

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Bethesda : Center for Cancer and Blood Disorders

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Bethesda : TG Therapeutics Investigational Trial Site

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Cumberland : Western Maryland Health System, Inc.

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Westminster : Alliance Hematology Oncology, PA

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Boston : Dana-Farber Cancer Institute

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Boston : Dana-Farber Cancer Institute

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Boston : Dana-Farber Cancer Institute

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Boston : Beth Israel Deaconess Medical Center

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Boston : Dana-Farber Cancer Institute

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Boston : Massachusetts General Hospital

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Boston : Dana Farber Cancer Institute

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Boston : Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Hyannis : Capecod Hospital / Davenport Mugar Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Worcester :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Worcester : Fallon Clinic

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Battle Creek :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Flint : Michigan State University / McLaren Regional Medical Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Flint : Genesee Cancer & Blood Disease Treatment Center, PC

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Freesoil : West Michigan Regional Cancer & Blood Center

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Grand Rapids : Cancer and Hematology Centers of Western Michigan

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Grand Rapids : Spectrum Health Hospitals

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Kalamazoo : West Michigan Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Rochester : Mayo Clinic

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Duluth : Duluth Clinic Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Minneapolis : Minnesota Oncology Hematology, PA

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Minneapolis : Minnesota Oncology Hematology P.A.

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Minneapolis : Novartis Investigative Site

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Rochester : Mayo Clinic

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

St. Louis Park : Park Nicollet Institute - Louisiana Ave.

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

St. Louis Park : Park Nicollet Institute Metro - MN CCOP

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Southaven : US Oncology - University of Tennessee Cancer Institute - Southaven

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Branson : Branson Oncology Clinic

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Columbia : US Oncology - Missouri Cancer Associates

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Jefferson City : Capitol Comprehensive Cancer Care Clinic

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Springfield : St. John's Medical Research Institute

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

St. Joseph : St. Joseph Oncology, Inc.

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

St. Louis :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

St. Louis : Washington University School of Medicine

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

St. Louis : Hematology Oncology Consultants, Inc.

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

St. Louis : St. Louis Hematology Oncology Specialists, Inc.

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

St. Louis : Washington University School of Medicine

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Missoula : Montana Cancer Institute Foundation

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Lincoln : Nebraska Hematology Oncology, PC

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Lincoln : Southeast Nebraska Hematology & Oncology Consultants, PC

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Omaha : University of Nebraska Medical Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Carson City : Sierra Nevada Oncology Care

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Las Vegas : Southern Nevada Cancer Research Foundation

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Las Vegas : Nevada Cancer Center

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Reno : VA Sierra Nevada Healthcare System

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Lebanon :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Cherry Hill : The Center for Cancer and Hematologic Disease

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Cherry Hill : The Center for Cancer and Hematologic Disease

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Elizabeth : Ellioth Fishkin, MD

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Englewood : Drs. Forte, Schleider, Attas & Condemi, PA

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Hackensack : Hackensack University Medical Center

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Hackensack : Hackensack University Medical Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Hackensack : Hackensack University Medical Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Hackensack :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Hackensack : Research Site Updated

AMG 319 Lymphoid Malignancy FIH

Morristown : Hematology Oncology Associates of Northern New Jersey

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Morristown : Hematology Oncology Associates of Northern New Jersey

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Morristown : Hematology Oncology Associates of Northern New Jersey

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Morristown : Charles Farber, MD

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Morristown : Hematology Oncology of Northern New Jersey

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Morristown : TG Therapeutics Investigational Trial Site

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

New Brunswick : Investigational Site Number 840001

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

Somerville : Steeplechase Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

New Hyde Park : CLL Research and Treatment Program

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

New Hyde Park : Biomedical Research Alliance of New York

Adults with Chronic Lymphocytic Leukemia are asked to participate in a research study being conducted by North Shore-Long Island Jewish Health System.

New Hyde Park : Biomedical Research Alliance of New York

Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia

New York : New York Presbyterian Hospital/Cornell Medical Center

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Rochester : Univ. of Rochester Cancer Center

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Albany : New York Oncology Hematology, P.C.

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Albany : Samuel S Stratton VAMC

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Bay Shore : Hematology Oncology Associates of Western Suffolk

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Bronx : Bronx River Medical Associates

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Bronx : Eastchester Center for Cancer Care

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Bronxville : Eduardo Saponara, MD

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Buffalo : Jonah Cancer Care Center & ECMC

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Dunkirk :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Johnson City : Broome Oncology

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Mount Kisco : Westchester Hematology Oncology Associates

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

New Hyde Park : Long Island Jewish Medical Center

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

New Hyde Park : Long Island Jewish Medical Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

New Hyde Park : Long Island Jewish Medical Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

New Hyde Park : Long Island Jewish medical Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

New Hyde Park : Long Island Jewish Medical Center

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

New Hyde Park : Long Island Jewish Medical Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

New York : Weill Cornell Medical College

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

New York : Memorial Sloan Kettering Cancer Center

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

New York : Weill Cornell Medical College

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

New York : Memorial Sloan Kettering Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

New York : Weill Cornell Medical College

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL

New York : Memorial Sloan-Kettering Cancer Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

New York : Weill Medical College of Cornell

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

New York : Mount Sinai School of Medicine & Mount Sinai Graduate School of biological Sciences

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

New York : Weill Cornell Medical College

Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies

New York : TG Therapeutics Investigational Trial Site

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

New York : Weill Medical College of Cornell

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Rochester : University of Rochester Medical Center

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Syracuse : SUNY Upstate Medical University - Adult Program

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Cary : US Oncology - Cancer Centers of North Carolina - Cary

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Durham : Research Site Updated

AMG 319 Lymphoid Malignancy FIH

Raleigh : US Oncology - Cancer Centers of North Carolina - Macon

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Raleigh : US Oncology - Cancer Centers of North Carolina - Falls

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Bismarck :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bismarck : Legacy Pharma Research

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Bismarck : Mid Dakota Clinic/Odyssey Research

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Fargo : Roger Maris Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Columbus : The Ohio State University

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Akron : Summa Health System - Cancer Research Office

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Akron : Summa Health System Hospitals

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Canton : Gabrail Cancer Center Research

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Canton : Nashat Y. Gabrail, MD, Inc.

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Cleveland : University Hospitals Case Medical Center

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Cleveland : Cleveland Clinic

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Columbus : The Ohio State University Comprehensive Cancer Center

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Columbus : The Ohio State University Medical Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Columbus : Mid Ohio Oncology / Hematology, Inc.

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Columbus : OSU

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Columbus : For additional information regarding sites for this trial call (919) 465-4648

Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab in Previously Untreated Chronic Lymphocytic Leukemia

Elyria : Hematology Oncology Center, Inc.

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Eugene : Willamette Valley Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Eugene : Willamette Valley Cancer and Research / USOR

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Eugene : US Oncology - Willamette Valley Cancer Institute - Eugene

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Portland : Northwest Cancer Specialists, PC

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Portland :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Portland : Oregon Health & Science University

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Portland : US Oncology - Northwest Cancer Specialists, PC - Portland - Barnes

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Portland : US Oncology - Northwest Cancer Specialists, PC - Portland - Broadway

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Portland : US Oncology - Northwest Cancer Specialists, PC - Portland - Hoyt

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Springfield : Willamette Valley Cancer Center

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Springfield : Willamette Valley Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Springfield : Willamette Valley Cancer Institute and Research Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Springfield : US Oncology - Willamette Valley Cancer Institute - Springfield

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Springfield : US Oncology Research: Willamette Valley Cancer Institute and Research Center

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Springfield : Willamette Valley Cancer Institute and Research Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Tualatin : Northwest Cancer Specialists, PC

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Tualatin : Northwest Cancer Specialists, PC

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Tualatin : Northwest Cancer Specialists, P.C.

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Tualatin : US Oncology - Northwest Cancer Specialists, PC - Tualatin

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Philadelphia : University of Pennsylvania, Abramson Cancer Center

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Bethlehem : Oncology Hematology of Lehigh Valley

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Drexel Hill : Consultants in Medical Oncology and Hematology, PC

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Gettysburg : Gettysburg Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Harrisburg : Andrews and Patel Associates

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Kingston : US Oncology - Medical Oncology Associates (Nahar)

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Lancaster : Lancaster Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Norristown : Luitpold Pharmaceuticals, Inc.

Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia

Philadelphia : Thomas Jefferson University

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Reading : Berks Hematology Oncology Associates

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Cranston : Hematology & Oncology Associates of Rhode Island

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Cranston : Sambandam and Joseph Associates, Inc

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Charleston : Charleston Hematology Oncology

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Charleston :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Charleston : Charleston Hematology Oncology Associates, PA

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Charleston : Charleston Hematology Oncology, PA

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Charleston : Investigational Site Number 840002

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

Charleston : Medical University of South Carolina

Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

Columbia : South Carolina Oncololgy Associates, PA

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Columbia : South Carolina Oncology Associates

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Easley : US Oncology - Cancer Centers of the Carolinas - Easley

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Greenville : Cancer Centers of the Carolinas

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Greenville : Cancer Centers of the Carolinas

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Greenville : Saint Francis Hospital

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Greenville : US Oncology - Cancer Centers of the Carolinas - West Faris

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Greenville : US Oncology - Cancer Centers of the Carlinas - Eastside

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Greenville : US Oncology - Cancer Centers of the Carolinas - Butternut

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Greenville : Greenville Hospital System

Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

Seneca : US Oncology - Cancer Centers of the Carolinas - Seneca

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Spartanburg : US Oncology - Cancer Centers of the Carolinas - Spartanburg

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Sioux Falls : Sanford Clinic

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Nashville : Vanderbilt-lngram

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Bartlett : US Oncology - University of Tennessee Cancer Institute - Bartlett

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Collierville : Family Cancer Center, PLLC

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Collierville : The Family Cancer Center

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Germantown : US Oncology - University of Tennessee Cancer Institute - Germantown

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Germantown : C. Michael Jones, MD, PC

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Memphis : US Oncology - University of Tennessee Cancer Institute - Memphis

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Nashville : Sarah Cannon Cancer Center

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Nashville : Sarah Cannon Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Nashville : Sarah Cannon Research Institute

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Nashville : Sarah Cannon Research Institute

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Nashville : SCRI

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Nashville : TG Therapeutics Trial Site

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Nashville : SCRI

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Nashville : Sarah Cannon Research Institute

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Houston : MD Anderson Cancer Center

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Abilene : US Oncology - Texas Cancer Center - Abilene (South)

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Amarillo : US Oncology - Texas Oncology, PA - Amarillo

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Amarillo : Texas Oncology

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Arlington : US Oncology - Texas Oncology - Arlington South

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Austin : Texas Oncology

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Bedford : Texas Oncology - Bedford

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Bedford : US Oncology - Texas Oncology, PA - Bedford

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Bryan : St. Joseph Regional Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

College Station : Scott & White Clinic

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Corpus Christi : South Texas Institute of Cancer

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Corpus Christi : Coastal Bend Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Dallas : Texas Oncology PA

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Dallas : Mary Crowley Cancer Research Centers - Medical City

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Dallas : Texas Oncology - Medical City Dallas

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Dallas : Texas Oncology - Dallas Presbyterian

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Dallas : US Oncology - Texas Oncology, PA - Dallas

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

El Paso : US Oncology - El Paso Cancer Treatment Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

El Paso : US Oncology - El Paso Cancer Treatment Center - West

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Fort Worth : Texas Oncology, P.A.

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Fort Worth : Texas Oncology, P.A.

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Fort Worth : Texas Oncology, P.A.

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Fort Worth : Texas Oncology - Fort Worth 12th Avenue

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Fort Worth : US Oncology - Southwest Fort Worth Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Fort Worth : US Oncology - Texas Oncology, PA - Fort Worth

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Fort Worth : JPS Center for Cancer Care

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Grapevine : US Oncology - Texas Oncology - Grapevine

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Houston : M.D. Anderson Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Houston : M.D. Anderson Cancer Center

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Houston : MD Anderson Cancer Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Houston : MD Anderson Cancer and Research Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Houston : MD Anderson Cancer Center / University of Texas

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Houston : MD Anderson Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Houston : Oncology Consultants

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Houston : University of Texas MD Anderson Cancer Center

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Houston : The University Of Texas Md Anderson Cancer Center

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Houston : M. D. Anderson Cancer Center at University of Texas

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Houston : UT MD Anderson Cancer Center

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)

Houston : Investigational Site Number 840003

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

Houston : University of Texas M.D. Anderson Cancer Center

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Houston : MD Anderson Cancer

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Houston : MD Anderson Cancer Center

TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

Kerrville : US Oncology - San Antonio Tumor & Blood Clinic - Kerrville

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Lackland AFB : Wilford Hall Medical Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Laredo : South Texas Research Alliance LLC Updated

A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

Laredo : South Texas Research Alliance LLC Updated

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Longview : US Oncology - Longview Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Lubbock : Joe Arrington Cancer Research and Treatment Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

McAllen : US Oncology - Texas Oncology - McAllen

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Mesquite : US Oncology - Texas Oncology - Mesquite

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Midland : US Oncology - Allison Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Paris : US Oncology - Texas Oncology - Paris

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Round Rock : Texas Oncology - Central Austin Cancer Center

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

San Antonio : Cancer Care Network of South Texas

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

San Antonio : Oncology of San Antonio Updated

A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

San Antonio : Cancer Care Centers of South Texas

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

San Antonio : Cancer Care Network of South Texas

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

San Antonio : Oncology of San Antonio Updated

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

San Antonio : US Oncology - Cancer Care Centers of South Texas

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

San Antonio : US Oncology - San Antonio Tumor & Blood Clinic - M. Oak

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

San Antonio : University of Texas Health Science Center, San Antonio

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Sherman : US Oncology - Texas Oncology - Sherman

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Temple :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Temple : Scott & White Healthcare Department of Research

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Tyler : ETMC dba Tyler Hematology Oncology

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Tyler : US Oncology - Texas Oncology - Tyler

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Tyler : ETMC dba Blood and Cancer Center - East Texas

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Waco : Texas Oncology - Waco

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Waco : US Oncology - Texas Oncology Cancer Care and Research Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Weslaco : US Oncology - Texas Oncology - Weslaco

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Wichita Falls : US Oncology - Texoma Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

American Fork : Central Utah Clinic

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Logan : Cache Valley Cancer Treatment & Research Clinic, Inc.

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Ogden : Northern Utah Associates

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Salt Lake City : Research Site Updated

AMG 319 Lymphoid Malignancy FIH

Charlottesville : Virginia University

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Abingdon : Cancer Outreach Associates, PC

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Arlington : US Oncology - Arlington Fairfax Hematology Oncology

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Charlottesville : University of Virginia Health System

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Christianburg : Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Christiansburg : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Christiansburg

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Fairfax : Virginia Cancer Specialists, PC

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Fairfax : Virginia Cancer Specialists, PC

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Fairfax : Virginia Cancer Specialists, PC

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Fairfax : US Oncology - Fairfax Northern VA Hem-Onc PC

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Gainesville : US Oncology - Fairfax - Northern Virginia Hematology-Oncology, PC - Gainesville

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Leesburg : US Oncology - Fairfax - Northern Virginia Hem-Onc, PC - Leesburg

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Low Moor : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Low Moor

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Richlands : Virginia Oncology Care, PC

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Richmond : Massey Cancer Center/Virginia Commonwealth University

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

Roanoke : Oncology and Hematology Associates of Southwest Virginia, Inc.

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Roanoke : Oncology and Hematology Associates of Southwest Virginia, Inc

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Roanoke : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Roanoke

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Salem : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Salem

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Winchester : US Oncology - Shenandoah Oncology - Winchester

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Woodbridge : US Oncology - Fairfax - Northern Virginia Hem-Onc, PC - Woodbridge

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Wytheville : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Wytheville

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Seattle : Fred Hutchinson Cancer Research Center

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Tacoma : MultiCare Health System

A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bellingham : Peace Health Medical Group

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Edmonds : Puget Sound Cancer Centers

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Edmonds : US Oncology - Puget Sound Cancer Center - Edmonds

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Everett : Providence Everett Medical Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Kennewick : Columbia Basin Hematology and Oncology

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Seattle : Seattle Cancer Care Alliance

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Seattle : Seattle Cancer Care Alliance

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Seattle : Seattle Cancer Care Alliance

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Seattle : US Oncology - Puget Sound Cancer Center - Seattle

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Seattle : University Of Washington School Of Medicine

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Seattle : Seattle Cancer Care Alliance

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Spokane : Cancer Care Northwest, US Oncology

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Spokane : US Oncology - Cancer Care Northwest - Holland

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Spokane : US Oncology - Cancer Care Northwest - Mission

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Spokane : US Oncology - Cancer Care Northwest - Sherman

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Spokane : Medical Oncology Associates PS

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Spokane Valley : Cancer Care Northwest

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Tacoma : Northwest Medical Specialties

A Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Vancouver : US Oncology - Northwest Cancer Specialists, PC - Vancouver - 134th St

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Vancouver : US Oncology - Northwest Cancer Specialists, PC - Vancouver - 136th St.

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Walla Walla : Providence St. Mary Regional Cancer Center

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Yakima : Yakima Valley Memorial Hospital/North Star Lodge

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Yakima : Yakima Valley Memorial Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Yakima : Yakima Valley Memorial Hospital / North Star Lodge

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Yakima : Yakima Regional Cancer Care

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Yakima : Yakima Valley Memorial Hospital / North Star Lodge

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Yakima : US Oncology - Yakima Valley Memorial Hospital/North Star Lodge (Boyd)

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Yakima : North Star Lodge Cancer Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Green Bay : St. Vincent Hospital/Green Bay Oncology

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Green Bay : St Vincent Regional Cancer Center

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Green Bay : Bellin Memorial Hospital

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Janesville : Mercy Health System Heme/Onc

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

LaCrosse : Gundersen Clinic

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Madison : University of Wisconsin

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Madison : University of Wisconsin Carbone Cancer Center

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Madison : University of Wisconsin

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Marshfield : Marshfield Clinic

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Milwaukee : Medical College of Wisconsin

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Milwaukee : Medical College of Wisconsin

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Milwaukee : Medical College of Wisconsin

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Milwaukee : Medical College of Wisconsin

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Oconomowoc : Oconomowoc Memorial Hospital

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Waukesha : Waukesha Memorial Hospital

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Waukesha : Waukesha Memorial Hospital

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Wisconsin Rapids : Riverview Hospital

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Buenos Aires :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Nedlands : Sir Charles Gairdner Hospital

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Feldkirch : LKH Feldkirch, Interne E

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Hall : A.ö. Bezirkskrankenhaus Hall in Tirol, Innere Medizin / Hämato - Onkologie

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Innsbruck : Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie

Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL

Innsbruck : Medical University Innsbruck, Division of Hematology and Oncology

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Innsbruck : Universitätsklinik Innsbruck, Innere MEdizin IV / Hämato-Onkologie

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Krems : Landesklinikum Krems, Hämato-onkologisches Service

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Kufstein : A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Linz : AKH Linz, Department für Innere Medizin 3

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Salzburg : Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin III

Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL

Salzburg : University Hospital Salzburg, Department of Medicine III, Center of Oncology and Hematology

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Salzburg : Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Steyr : Landeskrankenhaus Steyr, Department of Internal Medicine II (Hematology and Oncology)

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Steyr : Landeskrankenhaus Steyr, Innere Medizin, Hämatologie, Onkologie

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Wels : Hospital Wels-Grieskrichen, Department of Internal Medicine IV (Hematology and Oncology)

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Wels : Klinikum Wels-Grieskirchen GmbH, Abteilung für Innere Medizin IV

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Wien : AKH Wien, Klinische Abteilung für Hämatologie und Hämostaseologie

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Wien : Hanusch Krankenhaus, 3. Med. Abtlg.

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Antwerpen : Ziekenhuisnetwerk Antwerpen Updated

A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

Antwerpen : Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Antwerpen : Ziekenhuisnetwerk Antwerpen Updated

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Brussels : Institute Jules Bordet, Department of Hematology

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Brussels : Cliniques universitaires Saint-Luc

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Edegem : UZ Antwerpen

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Gent : UZ Gent

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Leuven : UZ Leuven

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Leuven : University Hospital Gasthuisberg, Department of Hematology

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Toronto : Univ. Health Network-Princess Margaret Hospital

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

Toronto : University Health Network - Princess Margaret Hospital

Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia

Winnipeg : CancerCare Manitoba

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

Tianjin : Hematologic hospital of Chinese academy of medical sciences

Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia

Brno :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Brno : FN Brno

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Hradec Kralove : FN Hradec Kralove

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Olomouc : FN Olomouc

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Praha : VFN Praha 2

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Praha : FN Kralovske Vinohrady

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Praha 10 :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret Updated

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974 AM1)

Creteil : Hôpital Henri Mondor

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Creteil : Hôpital Henri Mondor

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Creteil :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Montpellier :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Paris Cedex 13 :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Pessac :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Rouen : Centre Henri Becquerel

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Tours :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Villejuif :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Cologne : University Hospital Cologne

A Phase 3 Study of the Efficacy and Safety of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Cologne : German CLL Study Group

A Phase 3 Study of the Efficacy and Safety of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Dublin : Hermitage Medical Clinic

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Haifa :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Naharia :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ramat-Gan :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Rehovot : Kaplan Medical Center

The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Milano : Universita Vita-Salute San Raffaele

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Bergamo : A.O. Ospedali Riuniti di Bergamo U.S.C. Ematologia

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Bologna : University Hospital, Institute of Hematology and Oncology

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Brescia : Spedali Civili di Brescia

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Brescia : Presidi Ospedalieri Spedali Civili di Brescia Divisione di Ematologia

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Cagliari : Ospedale Oncologico Regionale A. Businco

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Cagliari : Ospedale Oncologico Regionale A. Businco

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Como : Ospedale Valduce S.C. Medicina Interna Sez. Ematologia

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Cremona : Istituti Ospitalieri di Cremona U.O.C. Ematologia e Centro Trapianti Midollo Osseo

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Genova : University Hospital San Martino, Department of Hematology and Oncology

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Legnano : Azienda Ospedaliera Ospedale Civile di Legnano U.O. Medicina Interna

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Lodi : ASL della Provincia di Lodi Presidio Ospedaliero di Lodi Dipartimento di Medicina Interna

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Milan : MSD Italia Updated

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974 AM1)

Milano : Ospedale San Raffaele S.r.l.

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Milano : Ospedale San Raffaele S.r.l.

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Milano : Ospedale San Raffaele S.r.l.

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Milano : Niguarda Ca'Granda Hospital

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Milano : University Scientific Research Institute San Raffaele

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Milano : IRCCS Fondazione Centro S. Raffaele del Monte Tabor Università Vita-Salute Dipartimento di Medicina Interna

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Milano : Ospedale Cà Granda - Niguarda S.C: Ematologia

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Milano : Ospedale Maggiore Policlinico Università di Milano Istituto di Ematologia

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Monza : Azienda Ospedaliera San Gerardo di Monza U.O. Ematologia

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Novara : Azienda ospedaliera-universitaria Maggiore della Carità SCDU Ematologia

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Padova : University School of Medicine, Department of Hematology

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Pavia : IRCCS Policlinico San Matteo Pavia Istituto di Ematologia

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Rozzano : IRCCS Istituto clinico Humanitas di Rozzano Dipartimento di Ematologia

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Torino : Azienda Ospedaliera Città della Salute e della Scienza di Torino

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Torino : A.O.U. Le Molinette San Giovanni Battista Divisione di Ematologia

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Venezia Mestre : Ospedale dell' Angelo

Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia

Brzozow :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chorzow :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Krakow :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Opole :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Slupsk :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Porto :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Arkhangelsk :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ekaterinburg :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Krasnodar :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Nizhniy Novgorod :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Obninsk N/A :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Perm :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Rostov-Na-Donu :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ryazan :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Saint Petersburg :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Samara :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Sochi :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

St. Petersburg :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

St.-Petersburg :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bansky Bystrica : F.D. Rossevelt hospital

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Bratislava : FNsP sv. Cyrila a Metoda

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Bratislava : Narodny onkologicky ustav

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Kosice : FNsP L.Pasteura

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Martin : Martinska fakultna nemocnica

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Presov : FNsP J.A. Reimana

Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Barcelona : Hospital de Ia Santa Creu i Sant Pau

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Barcelona : Hospital Clinic de Barcelona

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Coruna : Hospital Universitario A Coruna

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Madrid : Hospital de Madrid Norte-San Chinarro

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Madrid : Hospital Puerta de Hierro

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Pamplona : Clinica Universitaria de Navarra

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Badalona : Hospital Germans Trias i Pujol

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Barcelona : Hospital de la Santa Creu i Sant Pau

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Barcelona : Hospital Clinic de Barcelona

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Barcelona : Hospital Vall d'Hebron

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Barcelona : Hospital de la Santa Creu Sant Pau

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Córdoba : Hospital Universitario Reina Sofía

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia

Córdoba : Hospital Universitario Reina Sofía

Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia

Hospitalet de Llobregat : Institut Catala d'Oncologia

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Madrid : Hospital 12 de Octubre

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Madrid :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Madrid : Fundación MD Anderson Internacional

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia

Madrid : Hospital Universitario La Paz

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia

Madrid : Fundación MD Anderson Internacional

Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia

Madrid : Hospital Universitario La Paz

Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia

Madrid : Hospital La Princesa

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Madrid : Hospital Puerta de Hierro

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Oviedo : Hospital Central de Asturias

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Salamanca :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Salamanca : Hospital Clínico de Salamanca

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia

Salamanca : Hospital Clínico de Salamanca

Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia

Sevilla : Hospital Virgen del Rocío

Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia

Valencia : Hospital Clínico Universitario de Valencia

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia

Valencia : Hospital Clínico Universitario de Valencia

Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia

Valencia : Hospital Clinico

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Valencia : Hospital La Fe

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Zaragoza : Hospital Universitario Miguel Servet

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia

Zaragoza : Hospital Universitario Miguel Servet

Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia

Göteborg :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Stockholm :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Umeå :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ankara :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Istanbul :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Izmir :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Kayseri :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Cherkassy :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Dnepropetrovsk :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Donetsk :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Kharkiv :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Khmelnitskiy :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lviv :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Vinnitsa :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bournemouth : The Royal Marsden Hospital and The Institute of Cancer Research

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Canterbury : Kent & Canterbury Hospital

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Colchester : Colchester Hospital University

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Leeds : Kent & Canterbury Hospital

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Liverpool : Royal Liverpool University Hospital

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

London : Kings College Hospital. NHS Foundation Trust

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Nottingham : Nottingham City Hospital

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Southampton : Southampton General Hospital

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Sutton : The Royal Marsden Hospital and The Institute of Cancer Research

A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"

Birmingham :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bournemouth : Royal Bournemouth Hospital

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Bournemouth : Royal Bournemouth Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Dorchester : Dorset County Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Harrow : Northwick Park Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Harrow :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Leeds : St James's University Hospital

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Leeds : St James's University Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Leeds : St James's University Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Liverpool : Royal Liverpool University Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

London : Hammersmith Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

London : Hammersmith Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

London : Sarah Cannon Research Institute UK

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

London : King's College Hospital

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

London : University College London

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Manchester : Christie Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Manchester : The Christie NHS Foundation

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Newcastle upon Tyne : University of Newcastle Upon Tyne, NHS Foundation Trust

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Orpington : Princess Royal University Hospital

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Orpington : Princess Royal University Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Plymouth :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Salisbury : Salisbury District Hospital

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Salisbury : Salisbury District Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Sheffield Yorks :

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Southampton : Southampton General Hospital

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Southampton : Southampton General Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Torquay : Torbay District General Hospital

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Torquay : Torbay District General Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Truro : Royal Cornwall Hospital

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Truro : Royal Cornwall Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Yeovil : Yeovil District Hospital

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Yeovil : Yeovil District Hospital

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia Clinical Trials

Alabama

Arizona

California

Colorado

Connecticut

District of Columbia

Florida

Georgia

Hawaii

Idaho

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maryland

Massachusetts

Michigan

Minnesota

Mississippi

Missouri

Montana

Nebraska

Nevada

New Hampshire

New Jersey

New York

North Carolina

North Dakota

Ohio

Oregon

Pennsylvania

Rhode Island

South Carolina

South Dakota

Tennessee

Texas

Utah

Virginia

Washington

Wisconsin

Argentina

Australia

Austria

Belgium

Canada

China

Czech Republic

France

Germany

Ireland

Israel

Italy

Poland

Portugal

Russian Federation

Slovakia

Spain

Sweden

Turkey

Ukraine

United Kingdom